Haleon plc 6-K, filed Mar 18, 2025
Haleon plc (HLN)
6-K
2025-03-18
For: 2025-03-18
View Original
Added on
April 05, 2026
About this 6-K
Haleon plc filed this 6-K on March 18, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March
2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
18
March 2025 - “Proposed off-market purchase alongside
Pfizer”
|
99.1
Haleon plc: Proposed off-market purchase alongside Pfizer Inc.
offering
18 March 2025: Haleon plc
(the "Company" or "Haleon") (LSE/NYSE: HLN) notes the announcement
today by Pfizer Inc. ("Pfizer") of its proposed offering of
ordinary shares of £0.01 each in the Company to institutional
investors by way of an accelerated bookbuild offering process (the
"Proposed Offering").
Haleon has agreed with Pfizer to make an off-market purchase of
approximately £170 million worth of ordinary shares from
Pfizer, subject to (a) the offering price per ordinary share in the
Proposed Offering (the "Share Offering Price") being no more than
the price per ordinary share as at close of trading today on
the main market of the London Stock Exchange, and (b)
completion of the Proposed Offering.
Subject to completion of the off-market purchase, the purchase
price per ordinary share to be paid by Haleon to Pfizer will be
equal to the Share Offering Price.
The off-market purchase will represent a portion of the £500
million allocated to share buybacks in 2025 announced on 27
February 2025. Haleon intends to cancel the purchased ordinary
shares.
Further details will be provided following announcement by Pfizer
of the results of the Proposed Offering.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
||
|
Jo
Russell
|
+44
7787 392441
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Victoria
Durman
|
+44 7894 505730
|
|
Emma
White
|
+44
7823 523562
|
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information please visit www.haleon.com
Not for release, publication or distribution in the United States,
Canada, Japan, Australia or any other state or jurisdiction in
which such release, publication or distribution would be
unlawful.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date: March 18,
2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|